文献速递复苏、休克与脓毒症心脑血管急症重症综合管理与镇静镇痛

不可除颤院外心脏骤停中肾上腺素累积剂量与死亡模式:一项登记研究

Cumulative dose of epinephrine and mode of death after non-shockable out-of-hospital cardiac arrest: a registry-based study.
PubMed 文献 · Crit Care · 2023-12-20
一句话结论不可除颤院外心脏骤停ROSC后,CPR中肾上腺素累积剂量与早期心源性循环死亡强相关,作者认为需进一步临床研究限制肾上腺素剂量。

基于法国大巴黎地区SDEC登记(2011年5月至2021年12月)的前瞻性数据,纳入不可除颤院外心脏骤停复苏后ROSC并入住ICU的成人患者2792例,分析CPR期间肾上腺素累积剂量与ICU死亡模式的关系。出院存活242例(8.7%),心源性循环死亡1004例(35.9%),神经原因死亡1233例(44.2%),其他原因死亡313例(11.2%)。心源性循环死亡组肾上腺素用量为4.6 ± 3.8 mg,高于存活组的1.7 ± 2.8 mg、神经原因死亡组的3.2 ± 2.6 mg和其他原因死亡组的3.5 ± 3.6 mg(p < 0.001)。多因素分析显示累积剂量与心源性循环死亡强相关,校正复苏时长后仍成立。作者认为需进一步临床研究限制CPR期间肾上腺素剂量。

要点

  • 不可除颤院外心脏骤停ROSC后,心源性循环死亡组肾上腺素累积剂量为4.6 ± 3.8 mg,高于存活组1.7 ± 2.8 mg、神经原因死亡组3.2 ± 2.6 mg和其他原因死亡组3.5 ± 3.6 mg(p < 0.001)。
  • 心源性循环死亡比例随CPR中肾上腺素累积剂量线性增加(R2 = 0.92,p < 0.001):未用肾上腺素者为17.7%,累积剂量> 10 mg者为62.5%。
  • 多因素分析中,以0 mg为参照、出院存活为人群参照,肾上腺素累积1 mg与心源性循环死亡校正OR 3.45(95% CI 2.01-5.92)、2-5 mg OR 12.28(95% CI 7.52-20.06)、> 5 mg OR 23.71(95% CI 11.02-50.97),校正复苏时长后仍强相关。
  • 神经原因和其他原因死亡也与肾上腺素使用相关,但关联程度较弱。
  • 作者认为,旨在限制CPR期间肾上腺素剂量的进一步临床研究似乎是有必要的,PRS防治策略在未来试验中应考虑肾上腺素剂量。

适用人群与场景

  • 法国大巴黎地区SDEC登记(2011年5月至2021年12月)中,医疗性、心源性和非心源性原因导致的不可除颤院外心脏骤停复苏后ROSC并入住ICU的成人患者。

研究设计与关键结果

  • 研究类型:基于SDEC登记的前瞻性数据收集的登记研究;纳入2792例不可除颤院外心脏骤停ROSC后入住ICU的成人患者。
  • 死亡模式构成:出院存活242例(8.7%),心源性循环死亡1004例(35.9%),神经原因死亡1233例(44.2%),其他原因死亡313例(11.2%)。
  • 心源性循环死亡组肾上腺素累积剂量为4.6 ± 3.8 mg,存活组为1.7 ± 2.8 mg,神经原因死亡组为3.2 ± 2.6 mg,其他原因死亡组为3.5 ± 3.6 mg(p < 0.001)。
  • 心源性循环死亡比例随肾上腺素累积剂量线性增加(R2 = 0.92,p < 0.001):未用肾上腺素者为17.7%,累积剂量> 10 mg者为62.5%。
  • 多因素分析:以0 mg为参照、出院存活为人群参照,肾上腺素累积1 mg与心源性循环死亡的校正OR为3.45(95% CI 2.01-5.92),2-5 mg为12.28(95% CI 7.52-20.06),> 5 mg为23.71(95% CI 11.02-50.97),校正复苏时长后仍成立。
  • 神经原因和其他原因死亡也与肾上腺素使用相关,但关联程度较弱。

证据类型、等级与局限

  • 证据类型:基于登记的前瞻性数据收集的观察性研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,在不可除颤院外心脏骤停ROSC患者中,CPR期间肾上腺素剂量与早期心源性循环死亡强相关。
  • 作者认为,旨在限制CPR期间肾上腺素剂量的进一步临床研究似乎是有必要的;PRS防治策略在未来试验中应考虑肾上腺素剂量。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Epinephrine increases the chances of return of spontaneous circulation (ROSC) in out-of-hospital cardiac arrest (OHCA), especially when the initial rhythm is non-shockable. However, this drug could also worsen the post-resuscitation syndrome (PRS). We assessed the association between epinephrine use during cardiopulmonary resuscitation (CPR) and subsequent intensive care unit (ICU) mortality in patients with ROSC after non-shockable OHCA.

METHODS: We used data prospectively collected in the Sudden Death Expertise Center (SDEC) registry (capturing OHCA data located in the Greater Paris area, France) between May 2011 and December 2021. All adults with ROSC after medical, cardiac and non-cardiac causes, non-shockable OHCA admitted to an ICU were included. The mode of death in the ICU was categorized as cardiocirculatory, neurological, or other.

RESULTS: Of the 2,792 patients analyzed, there were 242 (8.7%) survivors at hospital discharge, 1,004 (35.9%) deaths from cardiocirculatory causes, 1,233 (44.2%) deaths from neurological causes, and 313 (11.2%) deaths from other etiologies. The cardiocirculatory death group received more epinephrine (4.6 ± 3.8 mg versus 1.7 ± 2.8 mg, 3.2 ± 2.6 mg, and 3.5 ± 3.6 mg for survivors, neurological deaths, and other deaths, respectively; p < 0.001). The proportion of cardiocirculatory death increased linearly (R2 = 0.92, p < 0.001) with cumulative epinephrine doses during CPR (17.7% in subjects who did not receive epinephrine and 62.5% in those who received > 10 mg). In multivariable analysis, a cumulative dose of epinephrine was strongly associated with cardiocirculatory death (adjusted odds ratio of 3.45, 95% CI [2.01-5.92] for 1 mg of epinephrine; 12.28, 95% CI [7.52-20.06] for 2-5 mg; and 23.71, 95% CI [11.02-50.97] for > 5 mg; reference 0 mg; population reference: alive at hospital discharge), even after adjustment on duration of resuscitation. The other modes of death (neurological and other causes) were also associated with epinephrine use, but to a lesser extent.

CONCLUSIONS: In non-shockable OHCA with ROSC, the dose of epinephrine used during CPR is strongly associated with early cardiocirculatory death. Further clinical studies aimed at limiting the dose of epinephrine during CPR seem warranted. Moreover, strategies for the prevention and management of PRS should take this dose of epinephrine into consideration for future trials.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Javaudin F, Bougouin W, Fanet L, et al. Cumulative dose of epinephrine and mode of death after non-shockable out-of-hospital cardiac arrest: a registry-based study. Crit Care. 2023. PMID: 38124126. doi:10.1186/s13054-023-04776-0

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。